Understanding the Market | DINGDANG HEALTH surged nearly 25% as the company continues to increase its investment in innovative drug layout, recently launching multiple innovative drugs

DINGDANG HEALTH surged nearly 25% during trading, and as of the time of publication, it rose 23.71% to HKD 1.20, with a transaction volume of HKD 12.7801 million. In terms of news, DINGDANG HEALTH continues to increase its investment in innovative drug layouts. Recently, DINGDANG HEALTH's pharmacy has launched the anti-tumor Class 1 innovative drug, hydrochloride lauroxil tablets, and has completed its first order service. Notably, DINGDANG HEALTH recently reached a cooperation agreement with Xiansheng Pharmaceutical, where Xiansheng Pharmaceutical's insomnia drug, daridorexant, made its O2O debut at DINGDANG HEALTH. Additionally, in early September, the company collaborated with Eli Lilly to launch teriparatide injection in pharmacies in Guangzhou and Shenzhen; in July, it partnered with Novo Nordisk to launch the weight management version of semaglutide. It is reported that since February of this year, DINGDANG HEALTH has cooperated with dozens of original drug companies to launch the "Original Drug Supply Guarantee Alliance."